The neuronal glycine transporter GLYT2 controls the availability of the neurotransmitter in glycinergic synapses, and the modulation of its function may influence synaptic transmission. The active transporter is located in membrane rafts and reaches the cell surface through intracellular trafficking. In the present study we prove that GLYT2 constitutively recycles between the cell interior and the plasma membrane by means of a monensinsensitive trafficking pathway. Also, a regulated trafficking can be triggered by PMA. We demonstrate that PMA inhibits GLYT2 transport by causing net accumulation of the protein in internal compartments through an increase of the internalization rate. In addition, a small increase of plasma membrane delivery and a redistribution of the transporter to non-raft domains is triggered by PMA. A previously identified phorbol-ester-resistant mutant (K422E) displaying an acidic substitution in a regulatory site, exhibits constitutive traffic but, in contrast with the wild-type, fails to show glycine uptake inhibition, membrane raft redistribution and trafficking modulation by PMA. We prove that the action of PMA on GLYT2 involves PKC (protein kinase C)-dependent and -independent pathways, although an important fraction of the effects are PKC-mediated. We show the additional participation of signalling pathways triggered by the small GTPase Rac1 on PMA action. GLYT2 inhibition by PMA and monensin also take place in brainstem primary neurons and synaptosomes, pointing to a GLYT2 trafficking regulation in the central nervous system.
The neuronal glycine transporter GLYT2 controls the availability of the neurotransmitter in glycinergic synapses, and the modulation of its function may influence synaptic transmission. The active transporter is located in membrane rafts and reaches the cell surface through intracellular trafficking. In the present study we prove that GLYT2 constitutively recycles between the cell interior and the plasma membrane by means of a monensinsensitive trafficking pathway. Also, a regulated trafficking can be triggered by PMA. We demonstrate that PMA inhibits GLYT2 transport by causing net accumulation of the protein in internal compartments through an increase of the internalization rate. In addition, a small increase of plasma membrane delivery and a redistribution of the transporter to non-raft domains is triggered by PMA. A previously identified phorbol-ester-resistant mutant (K422E) displaying an acidic substitution in a regulatory site, exhibits constitutive traffic but, in contrast with the wild-type, fails to show glycine uptake inhibition, membrane raft redistribution and trafficking modulation by PMA. We prove that the action of PMA on GLYT2 involves PKC (protein kinase C)-dependent and -independent pathways, although an important fraction of the effects are PKC-mediated. We show the additional participation of signalling pathways triggered by the small GTPase Rac1 on PMA action. GLYT2 inhibition by PMA and monensin also take place in brainstem primary neurons and synaptosomes, pointing to a GLYT2 trafficking regulation in the central nervous system.
INTRODUCTION
Glycine is the major inhibitory neurotransmitter in posterior areas of the vertebrate central nervous system [1] . The availability of the neurotransmitter in glycine-mediated synapses is controlled by Na + -and Cl − -dependent plasma membrane glycine transporters belonging to the SLC6 family [2] . The two glycine transporter isoforms, GLYT1 and GLYT2, display differential thermodynamic features, complementary cellular distributions and in vivo roles [3] [4] [5] [6] [7] . The neuronal transporter GLYT2 is mainly involved in the synaptic recycling of glycine to preserve the quantal glycine content inside synaptic vesicles, and it assists GLYT1 in regulating glycine levels at synapses [8] . GLYT2-deficient mice die prematurely during the second postnatal week displaying severe neuromotor alterations due to impaired inhibitory glycine transmission [7] . In addition, hypofunction of glycine signalling has been implicated in several pathologies such as neuromotor disorders, nociceptive pain or epilepsy and, recently, it was shown that some missense mutations in the gene encoding GLYT2 cause hyperekplexia or startle disease in humans [9] . Therefore increasing the efficacy of inhibitory glycine transmission would conceivably produce benefits in these disorders and it is reasonable to speculate that the modulation of GLYT2 activity might find therapeutic applications [8] . However, despite the essential role of GLYT2, the effects of the exogenous modulation of its activity on glycinergic function are presently unknown, as are the mechanisms that regulate GLYT2 activity in vivo. Consequently, the study of GLYT2 regulation may help in understanding the role of this transporter in glycinergic physiology and pathologies.
The SLC6 transporters are believed to be tightly regulated, the PKC (protein kinase C)-mediated regulation being one of the most studied mechanisms (see [10] [11] [12] [13] [14] for a review). Several lines of evidence indicate that activation of PKC by phorbol esters such as PMA or by stimulation of membrane receptors coupled to the phospholipase C/PKC pathway, leads to an acute reduction in transport activity and membrane expression of the monoamine transporters and the GABA (γ -aminobutyric acid) transporter GAT-1 among other members of the family [10, 13] . This seems to be due to a net increase of the internalization rate of the plasma membrane residing transporters [15] [16] [17] , although additional down-regulation of catalytic efficiency by PMA has been verified for the serotonin transporter [18, 19] .
We have previously shown that PMA inhibits GLYT2 transport activity and induces a decrease in plasma membrane transporters [20] . However, the detailed effects of PMA on GLYT2 trafficking and the signalling mechanisms that underlie PMA action on GLYT2 have not been studied. In the present study we focus on the trafficking properties of GLYT2 and demonstrate the existence of a monensin-sensitive constitutive traffic and a PMAregulated traffic. PMA inhibition is caused by removal of the transporter from the plasma membrane through an increase of the internalization rate and a smaller increase of plasma membrane delivery, resulting in a net accumulation of the protein in internal compartments. A PMA-resistant mutant harbouring K422E, an acidic substitution in the recently identified regulatory site around Lys 422 of GLYT2 [20] , fails to show glycine-uptake inhibition, membrane raft redistribution and trafficking modulation by PMA, but exhibits constitutive traffic. In addition, we show that GLYT2 down-regulation by PMA is mainly, but not exclusively, Abbreviations used: ECL, enhanced chemiluminescence; ERK, extracellular-signal-regulated kinase; GFP, green fluorescent protein; HBS, Hepesbuffered saline; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MDCK, Madin-Darby canine kidney; MEK, MAPK/ERK kinase; NET, noradrenaline (norepinephrine) transporter; NFPS, N[3-(4 -fluorophenyl)-3-(4 -phenylphenoxy)-propyl]sarcosine; NHS-SS-biotin, sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate; PKC, protein kinase C; SERT, serotonin transporter; TfR, transferrin receptor. 1 Correspondence may be addressed to either of these authors (email caragon@cbm.uam.es or blopez@cbm.uam.es).
due to PKC activation. The involvement of alternative signaltransduction cascades in transporter inhibition by PMA has been explored.
EXPERIMENTAL

Materials
Wistar rats were bred at the 'Centro [21] . The GLYT2 inhibitor ORG25543 [22] was donated by Dr Zoran Rankovic (Organon, Scotland, U.K.). The GLYT1 inhibitor NFPS {N[3-(4 -fluorophenyl)-3-(4 -phenylphenoxy)-propyl]sarcosine} was a gift of Dr Jesús Benavides (Sanofi-Aventis, Vitry sur Seine, France). All other reagents were obtained from Sigma-Aldrich.
Site-directed mutagenesis
GLYT2 substitution mutants were generated by site-directed mutagenesis using the method of Higuchi [22a] as previously described [23] using primers from Isogen. At least two independent Escherichia coli colonies carrying the mutant plasmids were characterized by sequencing and transport activity. GLYT2 or K422E in fusion with GFP (green fluorescent protein) in the pEGFPC1 vector were constructed as described (GFP-GLYT2) [24] .
Cell growth and protein expression
COS7 or MDCK (Madin-Darby canine kidney) cells (American Type Culture Collection) were grown at 37
• C and 5% CO 2 in high-glucose DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % fetal bovine serum. Transient expression was performed using Lipofectamine TM Plus (COS7 cells) or Lipofectamine TM 2000 (MDCK cells) from Invitrogen, following the manufacturer's protocol. Reproducible results were obtained with 60-70 % confluent cells on a 100-mm-dish using 4 μg of total DNA. Cells were incubated for 48 or 72 h at 37
• C until used.
Primary cultures of brainstem neurons
Brainstems from 16-day-old rat fetuses were isolated in HBSS (Hanks balanced salt solution; Invitrogen), and dissociated with activated papain (Papain Dissociation System; Worthington). The cells were resuspended in plating buffer (NB/B27, 50:1 by vol.; Invitrogen; 0.5 mM glutamine, 0.05 mg/ml gentamicin, 0.01 % streptomycin, 100 m-units/ml penicillin G and containing 5 % fetal calf serum). The cells were plated on poly-Llysine (13 μg/ml)-coated 24-well-plates at a density of 300 000 cells/well (for transport assays) or 40 000 cells/well on coverslips (immunofluorescence). Each day, half the well volume was replaced with fresh plating buffer without serum.
Glycine transport assay
Transport assays in COS7 cells or primary brainstem neurons were performed at 37
• C (unless otherwise indicated) in HBS [Hepesbuffered saline; 150 mM NaCl, 10 mM Hepes/Tris (pH 7.4), 1 mM CaCl 2 , 5 mM KCl, 1 mM MgSO 4 and 10 mM glucose] containing 2 μCi/ml [ 3 H]-labelled glycine (1.6 TBq/mmol; NEN Life Science Products), as described [20] . In COS7 cells, the transport solution was isotopically diluted at a final glycine concentration of 10 μM, and transport was measured by subtracting the glycine accumulation by mock-transfected COS7 cells (approx. 0.3 nmol of glycine/mg of protein per 6 min, representing approx. 20 % of the glycine transport by wild-type GLYT2) from that of the transporter cDNAtransfected cells and normalized by the protein concentration. In primary brainstem neurons, the transport solution contained, in addition to the labelled glycine, 5 μM NFPS and 2 mM of α-(methylamino) isobutyric acid, and L-proline, L-valine, L-alanine and L-leucine, to lower the background glycine accumulation. GLYT2-mediated glycine transport in neurons was defined as sensitive to ORG25543 (100 nM), and normalized for the protein concentration. All assays were performed in triplicate.
Immunofluorescence and confocal microscopy
Transfected MDCK cells were subjected to immunofluorescence as described previously [20] using rabbit or rat primary antibodies against the N-terminus of GLYT2 together with a mouse antiTfR antibody. Secondary antibodies were anti-rabbit or anti-rat antibodies coupled to Alexa Fluor ® 488 fluorophore for GLYT2 and anti-mouse antibodies coupled to Alexa Fluor ® 555 for TfR. Alternatively, cells were transfected with GLYT2 fused to GFP in the pEGFPC1 vector (GFP-GLYT2) [24] and were fixed with 4 % paraformaldehyde in PBS. The cells were visualized by confocal microscopy on a Microradiance Bio-Rad machine using a vertical Axioskop 2 microscope (Zeiss) or LSM510 META coupled to an inverted microscope AXIOVERT200 (Zeiss).
Pharmacological treatments
For acute treatments, transfected or mock-transfected COS7 cells, MDCK cells or primary brainstem neurons were serumstarved for 3 h at 37
• C and then incubated in HBS at 37
• C for 30 min (if not otherwise indicated in the Figure legends) with vehicle, monensin (20 μM) or PMA (0.01-1 μM), alone or with the indicated additions. All of the compounds were freshly prepared and protected from light. Cells were then extensively washed, and fixed for immunofluorescence labelling, assayed for glycine-transport activity or solubilized for lipid raft isolation. For chronic PMA treatment, transfected or mock-transfected COS7 cells were incubated overnight (16 h) with 1 μM PMA in culture medium, washed with HBS and serum-starved for 3 h in this medium. Subsequent acute PMA treatment was performed as above.
Cell-surface labelling
Surface labelling in steady-state conditions was performed as described previously [20, 25] , by maintaining the samples at 4
• C during all of the steps. Transfected or mock-transfected cells, were washed 3× with HBS, allowed to stand for 15 min, and incubated for 20 min with 1.5 mg/ml sulfo-NHS-SS-biotin. Wells were washed twice with 100 mM L-lysine in HBS, and incubated in the same medium for 45 min. Cells were scraped [scraping buffer was 50 mM Tris, 150 mM NaCl, 0.4 mM PMSF and 0.004 mM pepstatin (pH 7.4)], quantified for protein concentration and equal amounts of protein were lysed for 30 min by supplementing the buffer with 5 mM EDTA, 1 % Triton X-100, 0.1 % SDS and 0.25 % sodium deoxycholate. After cell debris removal, an aliquot was brought to 1×Laemmli buffer (total fraction). To the remaining lysate, 40 μl of prewashed streptavidin-agarose beads (Sigma) were added and incubated for 2 h at room temperature (22
• C) with end-over-end shaking. Beads were pelleted and biotinylated proteins were eluted with Laemmli buffer. Samples were run on an SDS/PAGE gel (7.5 % gel), subjected to Western blot with ECL detection and quantified on a GS-710 calibrated imaging densitometer from Bio-Rad with Quantity One software by using film exposures in the linear range as described [19] . Control load was performed by calnexin reprobing of Western blot membranes.
Delivery of GLYT2 transporters to the plasma membrane
Biotinylation under trafficking-permissive conditions was carried out as above but cells were rinsed with HBS prewarmed at 37
• C prior to incubation with sulfo-NHS-SS-biotin for the desired times at this temperature in the presence of 1 μM PMA or vehicle [26] . Protein trafficking was stopped by placing the cells on ice and all of the subsequent steps, including rinsing with HBS and residual biotin quenching, were performed at 4
• C and samples were processed as above. An aliquot of the cells was treated in parallel with sulfo-NHS-SS-biotin at 4
• C to determine initial surface protein.
Internalization of GLYT2 transporters
Reversible biotinylation was performed as described in [27] . COS7 cells were surface-labelled at 4
• C as above and part of the biotinylated cells were washed and kept at 4
• C to provide a measure of the total pool of cell-surface transporter available for internalization and strip efficiencies. The rest of the cells were washed with prewarmed (37
• C) HBS supplemented with 0.2 % BSA and 0.18 % glucose (HBSbg) and incubated at 37
• C for 2 min. Endocytosis was allowed to proceed for various periods of time at 37
• C in the absence/presence of 1 μM PMA or vehicle. Traffic was stopped by placing plates in an ice bath and washing twice with ice-cold HBS. Residual cell-surface biotin was stripped with freshly prepared NT buffer [50 mM MesNa, 150 mM NaCl, 1 mM EDTA, 0.2 % BSA, 0.18 % glucose and 20 mM Tris (pH 8.6)] for 25 min. In this condition we observed a residual surface biotin of approx. 10 %. Cells were lysed and processed as above.
Isolation of detergent-resistant membranes
Membrane rafts from transfected MDCK cells or from rat brainstem synaptosomes were isolated according to standard procedures [28] with variations. Scraped washed cells or purified synaptosomes were lysed at 2 mg of protein/ml in MBS buffer [25 mM Mes and 150 mM NaCl (pH 6.5)], containing 0.5 % Triton X-100 and protease inhibitors (PI, 0.4 mM PMSF + Sigma cocktail) at a detergent/protein ratio of 3.33. Cells were solubilized by incubation for 30 min at 4
• C and homogenized in a Dounce homogenizer (10 strokes). Synaptosomal membranes [25] were solubilized by passing them through a 25-gauge-needle followed by a 30 min incubation at 4
• C. Equal volumes of 80 % (w/v) sucrose were added to the lysates and mixed thoroughly. Lysed samples (4 ml) in 40 % sucrose were overlaid successively with 4 ml of 30 % and 5 % sucrose (in MBS + PI) in a SW40 ultracentrifuge tube. After centrifugation at 38 000 rev./min (SW40 rotor, Beckman) for 18 h at 4
• C, 1 ml fractions were collected from the top. The proteins in each fraction were precipitated with 10 % ice-cold trichloroacetic acid, and subjected to SDS/PAGE (10 % gel) and immunoblotting.
Data analysis
Non-linear regression fits of experimental data were performed with ORIGIN (Microcal Software). The effect of inhibitors on uptake was expressed and processed as reported previously [23] .
The kinetic parameters of GLYT2 delivery or internalization to or from the plasma membrane were calculated as described in [16] by fitting the time course of biotinylated transporter at 37
where A is the maximum band density, t is the time (in min) and τ is the time constant of the process, the inverse of which is a measure of the exo-or endocytosis rate. Statistical analyses on transport data or band densities were performed using ANOVA with Bonferroni's post-hoc analysis or a Student's t test.
RESULTS
Regulated and constitutive traffic of GLYT2
Previous studies by our group have shown that GLYT2, expressed either in heterologous systems such as COS7 or PC12 cells or in native systems such as synaptosomes or primary neurons, distributes between the cell surface and the intracellular compartment in a proportion that is characteristic of the expression system [20, 24, 25] . This suggests that the steady-state distribution of the transporter is controlled by a constitutive intracellular traffic, which can be deviated from steady-state conditions by regulatory agents such as neuronal activity or phorbol esters [20, 24, 25] . To establish whether GLYT2 inhibition by PMA involves dynamic trafficking, in the present study we have treated COS7 cells expressing GLYT2 with PMA at trafficrestrictive (18 • C) and traffic-permissive (37 • C) temperatures and monitored transport activity and transporter membrane expression ( Figure 1 ). As expected, a 30 min incubation with increasing PMA concentrations at 37
• C caused a maximal 30-40 % reduction of glycine transport by GLYT2 and a parallel decrease in biotinylated transporter together with an increase in intracellular non-biotinylated protein ( Figures 1B and 1C) . Conversely, there was neither transport inhibition nor loss of plasma membrane GLYT2 when PMA treatment was performed at 18
• C, indicating that trafficking of the transporter is needed for PMA inhibition to take place. Some SLC6 transporters have been shown to be constitutively internalized and recycled to the plasma membrane. One way to study constitutive protein trafficking is to use the proton ionophore monensin, which collapses the proton gradients that maintain the acidic pH within the intracellular organelles, and interferes with endosomal trafficking [15] . Figures 2(A) and 2(B) show that monensin treatment of COS7 cells expressing GLYT2 for 30 min caused a decrease in the amount of surface transporter in a comparable manner as did PMA, and the combined addition of both drugs produced a higher plasma membrane GLYT2 down-regulation. Parallel glycine uptake measurements confirmed the loss of functional surface GLYT2 by monensin ( Figure 2C ). We also studied transporter surface expression by immunofluorescence and confocal microscopy in cells expressing GLYT2. MDCK cells are better tools than COS7 cells for transporter visualization because more GLYT2 is located in basal conditions at the cell surface and, therefore, vehicle-treated cells showed an intense surface fluorescence ( Figure 2D ). Monensin treatment decreased the amount of plasma membrane transporter and caused an accumulation of the protein in intracellular structures where GLYT2 ( Figure 2D , green fluorescence) partially co-localized with the endosomal marker TfR ( Figure 2D , red fluorescence) [29] . As monensin produces a broad endosomal trafficking block, the accumulated intracellular transporter could be due to a recycling blockade but also to a monensin lateendosomal trafficking obstruction; however, we did not observe intracellular transporter accumulation in cells treated in parallel with chloroquine ( Figure 2D ). This, together with the decrease in biotinylated transporter by monensin (Figures 2A and 2B ), strongly suggests that GLYT2 undergoes constitutive recycling and accumulates in intracellular compartments by continuous internalization under recycling blockade.
Effect of PMA on glycine transport and surface expression of wild-type GLYT2 and a K422E mutant
In a previous study, we identified Lys 422 as a regulatory site of glycine transport activity by GLYT2. The substitution of this residue by acidic amino acids conferred resistance to PMA [20] . Figures 3(A) and 3(B) show that PMA treatment of COS7 cells expressing GLYT2 produced a dose-and time-dependent inhibition of glycine transport that did not occur in cells expressing K422E. The action of PMA was not a result of non-specific phorbol ester effects, because the inactive analogue 4α-PDD (4α-phorbol 12, 13-didecanoate) did not inhibit GLYT2 [20] . [20] ), whereas K422E was resistant to the phorbol ester (no V max modification although the K m reduction was still observed [20] ).
The above functional data, in agreement with results presented in Figure 1 , suggest that the GLYT2 V max decrease is due to a PMA-induced removal of the wild-type transporter protein from the plasma membrane. In order to study the action of PMA on the trafficking features of the K422E mutant, we studied transporter surface expression by confocal microscopy in MDCK cells expressing GLYT2 transporters fused with GFP, a construct that has been previously characterized [24] (Figure 3C ). Treatment with PMA promoted intracellular accumulation of GFP-GLYT2 in approx. 70-80 % of the cells in a comparable extent as did monensin, and a slightly higher effect was observed by the combined addition of both drugs (PMA + monensin). PMA-induced intracellular accumulation was also observed in the presence of the phosphatase inhibitor okadaic acid and was reversed by the general kinase inhibitor staurosporin, suggesting the involvement of protein kinases in the action of PMA on GLYT2. In contrast, Figure 3(D) shows that the GFP-K422E mutant did not increase its abundance in the cell interior in response to PMA (only in 5-10 % of the cells) despite its low basal membrane expression ( [20] and see below). It is of interest to note that the K422E mutant was sensitive to monensin, which produced protein accumulation in intracellular compartments (75 % of the cells) as it did for wild-type GLYT2. This result suggests that mutation of Lys 422 abolishes PMA-modulated GLYT2 trafficking but not its constitutive trafficking.
Effect of PMA on delivery and internalization rates
Since membrane expression results from a dynamic equilibrium between membrane delivery and internalization, we used modified biotinylation assays to detect protein trafficking to and from the plasma membrane. Transporter delivery to the cell surface was estimated by biotinylating transfected COS7 cells at 37
• C in the presence of PMA or vehicle in order to label proteins that cycle through the plasma membrane. Surface-labelled transporters were collected on streptavidin-agarose beads and subjected to immunoblot with GLYT2 antibodies. Parallel biotinylation assays under non-trafficking permissive conditions (4 • C), allowed us to measure transporter steady-state surface expression. At 4
• C, 20.5 + − 2.5 % of total GLYT2 and 8.4 + − 2.7 % of total K422E were labelled, in agreement with the lower membrane expression of the mutant [20] . These values were invariant during the time frames of our experiments (results not shown). Figures 4(A) and 4(B) show representative immunoblots for GLYT2 ( Figure 4A ) and K422E ( Figure 4B ). Under the conditions used in the present study, the membrane-impermeant biotinylating reagent was unable to label intracellular proteins (less than 8 % of total calnexin immunoreactivity in the biotinylated fraction). Within 5 min there was an approx. 2-fold increase in the amount of biotinylated transporters and an approx. 3-fold increase was detected in a plateau reached within 15 min. This time-dependent increase was accompanied by a decrease in the amount of transporter in the non-biotinylated fraction and no change in the total transporter amount. By measuring the amount of transporter labelled at 37
• C at increasing incubation times over the transporter labelled at 4
• C for both wild-type and mutant, the delivery rates can be compared [16, 26, 27] . Average time courses of membrane insertion ( Figures 4A and 4B , lower panels) were fitted by a single exponential function as described in the Experimental section, and estimations of the basal delivery rates were obtained (0.109 + − 0.02 and 0.119 + − 0.03 min −1 for GLYT2 and K422E respectively). PMA promoted a modest and similar increase in the estimated exocytosis rates of the two transporters (0.132 + − 0.03 and 0.141 + − 0.05 min −1 ), suggesting that mutant resistance to PMA is not related to a differential alteration of the delivery of the transporter. In addition, under PMA treatment the wild-type and mutant recycling transporter pools were increased by approx. 25-30 %. We next examined GLYT2 transporter internalization using a reversible biotinylation strategy. To do this, surface transporters were labelled with a disulfide-bond-containing biotinylating reagent at 4
• C and then permitted to internalize (at 37 • C) for increasing times in the presence of PMA or vehicle. The transporter labelled at 4
• C represents the maximal amount that could be internalized and it is a measure of the steady-state surface protein, which was specific to each GLYT2 transporter (see above). At the end of the internalization time, surface biotin was removed by MesNa, a membrane-impermeant reducing agent, and biotinylated transporters were isolated and quantified. In our experimental conditions, an 85-90 % efficiency of biotin stripping was determined by MesNa treatment at 4
• C (results not shown). Figures 4(C) and 4(D) show representative immunoblots and densitometric analysis for GLYT2 ( Figure 4C ) and K422E ( Figure 4D) . A plateau was reached within 15 min in which approx. 30-35 % of surface transporters were protected from MesNa. No further increases in accumulated transporters were observed at higher incubation times, supporting rapid recycling of the internal pool. By fitting the experimental internalization results as above, the basal intracellular accumulation rates were found to be 0.115 + − 0.06 and 0.402 + − 0.1 min −1 for GLYT2 and K422E respectively. This indicates a more rapid basal internalization by the mutant, in accordance with its lower membrane expression [20] . PMA treatment accelerated the basal internalization rate of GLYT2 wild-type by approx. 2.5-fold, resulting in an accumulation rate of 0.292 + − 0.07 min −1 (n = 4, significantly different from vehicle-treated cells, P < 0.05 using a Student's t test), whereas no increase was observed for K422E (0.460 + − 0.09 min −1 ). In addition, no alteration of the endocytosed transporter pool sizes was detected. Taken together, our delivery and internalization experiments suggest that PMA shifts GLYT2 trafficking, but not K422E mutant traffic, towards internal compartments by increasing endocytosis to a higher extent than exocytosis.
Effect of PMA on transporter association with membrane rafts
We have recently shown that GLYT2 is associated with membrane rafts in the neuronal plasma membrane and that the removal of cholesterol and sphingolipids impairs both raft-association and GLYT2 activity [30] . Since the lipid environment may constitute a new mechanism to modulate GLYT2 transporter activity, we wanted to examine the effects of PMA on membrane raft localization. Transporter-expressing MDCK cells were treated with vehicle or PMA at 37
• C and then solubilized with Triton X-100 at 4
• C. Detergent-resistant membranes were separated by sucrose-density centrifugation ( Figure 5 ). Western blotting of the gradient fractions showed that wild-type GLYT2 and the K422E mutant were present in membrane raft light fractions (fractions 4 and 5) together with the raft marker flotillin-1, whereas proteins excluded from rafts, such as the TfR, were exclusively found in high-density fractions. Densitometric analysis of the fractions revealed approx. 17 + − 2 % of the total GLYT2 and 18 + − 3 % of the total K422E in the light fractions. Treatment of cells with PMA displaced GLYT2 from the raft to the non-raft fractions (fractions 9-12) so that only approx. 1 + − 0.8 % of total transporter remained in light fractions with a concomitant increase in the non-raft fractions. However, the K422E mutant did not show any change in fraction distribution under PMA (19 + − 3 % in light fractions). Also the localization of the markers flotillin-1 and TfR in the gradient fractions was not altered by PMA.
PKC involvement in GLYT2 inhibition by PMA
PMA is a potent PKC activator, but there are other cellular phorbol ester receptors that may trigger different signalling cascades including Ras-GRP, chimaerins, Munc13 or protein kinase D [31, 32] . In order to know whether the action of PMA on GLYT2 was mediated by PKC, we used pharmacological tools. As shown in Figure 6 (A), the general serine/threonine and tyrosine kinase inhibitor staurosporin fully reversed the GLYT2 transport inhibition [20] , and the trafficking modulation by PMA (see Figures 3C and 3D ). In addition, the bisindolylmaleimide GF109203X, which is the most specific inhibitor of PKC, produced a robust, though not total, reversion of glycine transport down-regulation ( Figure 6B ). Furthermore, chronic PMA treatment of COS7 cells, a procedure that effectively downregulates classic and novel PKC isoforms ( Figure 6C , upper panel), reduced, by approx. 40 %, the inhibition produced by 1 μM acute PMA on expressed GLYT2 ( Figure 6C ). These results indicate that PMA action on GLYT2 may involve PKC-dependent and -independent pathways, although an important fraction of the effects are PKC-mediated. Conversely, PKC does not appear to be involved in constitutive traffic, since the reduction of biotinylated GLYT2 by monensin remained unchanged after PKC down-regulation (78 % and 79 % of the vehicle-treated transporter remained at the plasma membrane after monensin treatment in control or chronic PMA respectively; Figure 6D , upper panel). In addition, glycine-transport inhibition by the ionophore was not significantly modified after PKC down-regulation (40 + − 7.5 % compared with 33 + − 7.1 % after chronic PMA; Figure 6D ).
We have initiated the search of the signalling pathways that may additionally mediate PMA effects on GLYT2 by examining how the inhibition of key proteins of potentially implicated cascades affects PMA action. The results presented in Figure 7 indicate that pretreatment of COS7 cells expressing GLYT2 with the PKC inhibitor GF109203X produced the maximal decrease in GLYT2 inhibition by PMA (32 + − 2.5 % became 12 + − 2.6 % inhibition), confirming that PKC activation is the main event involved. However, a significant reduction of PMA action could be observed in the presence of an inhibitor of the small GTPase Rac1 (32 + − 2.5 % inhibition was reduced to 21 + − 3.2 %). Since Rac1 can trigger regulatory cascades of cytoskeletal dynamics [33] , this suggests the involvement of such pathways in GLYT2 regulation. Moreover, none of the remaining compounds assayed was able to diminish GLYT2 inhibition by PMA. The inactivation of the Ras exchange factors Ras or Ras-GRP with a farnesyl transferase inhibitor (FTPinhIII) had no effect on PMA inhibition, indicating that Ras is not upstream of Rac1 in this pathway as described in other systems [33] . This may discount the activation of the MAPK (mitogen-activated protein kinase) pathways by Ras from being responsible for PMA-induced GLYT2 down-regulation. In addition, owing to the reported possibility of MAPK cascade activation by Rac1 signalling [34] we used inhibitors of ERK (extracellular-signal-regulated kinase) [U0126 for MEK (MAPK/ERK kinase) 1/2 and PD98059 for MEK1], p38MAPK (SB203580 and PD169316) and JNK (c-Jun N-terminal kinase; SP600125). The PMA inhibition was not decreased, and even a small increase was detected, suggesting that MAPKs are not involved in the PMA action on GLYT2 (see below). Finally, the involvement of PI3K (phosphoinositide 3-kinase) or phospholipase C was discarded as their respective inhibitors, LY292002 and U73122, did not alter the extent of PMA-induced GLYT2 down-regulation.
GLYT2 down-regulation by monensin and PMA also takes place in brainstem primary neurons and synaptosomes
The COS7 cell heterologous expression system permits us to analyse the differential responses by wild-type and mutant GLYT2 transporters. However, we wished to know whether the observed constitutive and regulated trafficking properties of GLYT2 were also relevant in a brain-derived preparation. Figure 8(A) shows that incubation of rat brainstem primary neurons with monensin also decreased the amount of plasma membrane GLYT2 (approx. 60 % of surface protein remained after 15 min treatment) and its glycine transport was inhibited with an even higher potency than in heterologous systems ( Figure 8B ). In addition, increasing concentrations of PMA produced a dose-response inhibition of endogenous GLYT2 activity ( Figure 8C ). The IC 50 for PMA inhibition (19.7 + − 0.6 nM) and the maximal reduction of GLYT2 activity (approx. 30 % at 0.2 μM glycine), are comparable with that achieved in the heterologous system (see above). As revealed in Figure 8(D) , PMA treatment of brainstem neurons decreased kinetic parameters of the glycine transport by GLYT2 to a greater extent than in COS7 cells. V max was reduced from 9.6 + − 0.8 to 2.7 + − 0.5 nmol of glycine/mg of protein per 15 min in control and PMA treatments, and K m decreased from 36.3 + − 7.3 to 16.6 + − 3.0 μM. These values represent an approx. 70 % and 50 % reduction in V max and K m respectively. Moreover, isolation of membrane rafts from rat brainstem synaptosomes after PMA treatment demonstrated that GLYT2 present in raft fractions was also displaced to the non-raft fractions by the drug ( Figure 8E ). According to results in cells (see above), approx. 12 + − 3 % of the total GLYT2 and 40 + − 6 % of the flotillin-1 were in the light fractions in basal conditions. Under PMA treatment, only 1 + − 0.5 % of total transporter but 39 + − 4 % of total flotillin-1 remained in raft fractions ( Figure 8F ). These results suggest that GLYT2 is subjected to regulated and constitutive trafficking and point to a role of PKC in the modulation of the transporter in the central nervous system.
DISCUSSION
Different studies with knockout animals and the investigation of the regulatory properties of neurotransmitter transporters, have led to the belief that the modulation of the expression and/or the activity of plasma membrane transporters influences neurotransmission [4] [5] [6] [7] [8] 12] . In the present study we analyse the trafficking features of the neuronal glycine transporter GLYT2 and establish, for the first time, the existence of a constitutive and regulated traffic of the protein. To observe GLYT2 constitutive internalization, we have used the carboxyl ionophore monensin, which blocks recycling by increasing the pH in endosomes [15] . Monensin reduced the amount of surface-biotinylated GLYT2 causing a parallel transporter accumulation in TfR-containing endosomes. The intracellular GLYT2 clusters observed by confocal microscopy under monensin treatment could not be mimicked by inhibiting lysosome processing, discarding the interference with the late-endosomal trafficking as the main cause of transporter accumulation [35] . Therefore the monensin effect was due to the obstruction of GLYT2 constitutive traffic that, consequently, produced glycine transport inhibition. We could not however rule out a marginal direct inhibition of the ionophore on GLYT2 activity, especially in primary neurons [15] . The present study also establishes the requirement of GLYT2 trafficking for PMA regulation as it takes place at 37
• C but not at 18
• C, a temperature that is expected to produce a considerable inhibition of general trafficking [15, 27] . Traffic involvement was further supported by confocal microscopy and surface biotinylation showing that GLYT2 transporter removed from the plasma membrane was accumulated in internal compartments through an increase of the internalization rate and a lower increase of plasma-membrane delivery. The biotinylation of live cells at 37
• C has been validated for GLYT2 through parallel measurements of TfR trafficking (results not shown) as shown for related plasma membrane proteins [16, 26, 27, 36, 37] , and by verifying the absence of artifactual GLYT2 internalization by the biotin reagent [15] . Using this method, we estimated GLYT2 delivery and internalization rates that are similar to those measured for related transporters in non-neural cells [17, 26, 36] , although trafficking velocities higher than those have been determined for the GAT-1 transporter in neurons [16] probably due to cell-specific mechanisms. It should be noted, however, that our results may represent an overestimation of the transporter delivery due to more efficient protein labelling at 37
• C, and an underestimation of its endocytosis rate due to rapid recycling interference [26, 38] . Nevertheless, by estimating in parallel the relative trafficking rates of GLYT2 and a phorbol-esterresistant mutant K422E, the effects of PMA could be compared. We determined a 2.5-fold increase in GLYT2 endocytosis rate under PMA treatment, according to enhancements detected for other transporters [13, 16, 17, 36] . In addition, we measured a delivery increase by PMA that affects both the GLYT2 wildtype and the phorbol-ester-resistant K422E mutant used in the present study [20] . This mutant fails to show transport inhibition, internalization enhancement and membrane raft displacement by PMA, indicative of differential regulatory properties. The upregulation of delivery may explain the net increase in glycine transport by the K422E mutant that was occasionally observed in response to PMA (see Figure 3 and [20] ). The response of wild-type and the mutant to monensin suggests that the mutation of Lys 422 abolishes regulated, but not constitutive, traffic. Lys 422 is a crucial residue for glycine transport that maintains a conformational connection with the glycine binding/permeation site [20] . Based on the high-resolution structure of LeuTa, a prokaryotic homologue of the SLC6 transporters [39] , it was shown that this residue lies in the N-terminal portion of the fifth transmembrane helix, near the cytoplasmic substrate-permeation pathway [40] . This situation is optimal for a regulatory residue and indeed, after its establishment in GLYT2 [20] , positions with a regulatory role were described in homologous regions of NET [noradrenaline (norepinephrine) transporter] and SERT (serotonin transporter) [36, 41] . The simultaneous phosphorylation of two NET residues close to this position is linked to PMA-dependent internalization. The substitution of these residues in GLYT2 with neutral or acidic amino acids produces single mutants partially resistant to PMA [20] . The similar properties of NET and GLYT2 mutants suggest that these residues could function as phosphoacceptors also in the latter. The specific roles of phosphorylation within the SLC6 transporters [18, 42, 43] , requires further investigation.
One interesting question is whether the action of PMA on GLYT2 trafficking accounts for the whole inhibitory effect of GLYT2 transport. The results of the present study suggest that most of the PMA-induced GLYT2 inhibition is due to surface transporter removal (see Figure 1) . However, the diminution in glycine transport V max by PMA was higher (approx. 60 %) than the detected reduction of surface transporter (approx. 40 %). As PMA displaces GLYT2 from its optimal location in cholesterol-rich membrane rafts, and GLYT2 activity is regulated by the lipid environment [30] , the modulation of transporter function may result from both its trafficking regulation and its activity regulation. This could explain a lower V max than expected from surface-transporter reduction. Another question is the relationship between membrane raft redistribution and transporter internalization. The fraction of GLYT2 that is raft redistributed, although representing a small percentage of the total transporter (approx. 15 % in synaptosomes), seems to account for the whole amount of transporter present at the surface (only approx. 5-10 % of total GLYT2 is biotinylated in synaptosomes, and 60 % of synaptosomal GLYT2 rafts are surface located; [30] ). We propose that internalization may selectively affect raftassociated GLYT2. Indeed, our unpublished results indicate that MβCD and filipin block PMA action, therefore suggesting that raft location is necessary for PMA internalization (A. Fornés, E. Núñez, P. Alonso-Torres, C. Aragón and B. López-Corcuera, unpublished work).
One important conclusion of the present study that currently remains unanswered is the involvement of PKC in GLYT2 inhibition by PMA, and the relevance of this modulation in brainderived preparations pointing to a GLYT2-trafficking regulation in the central nervous system. Our results indicate that PMA action on GLYT2 may involve PKC-dependent and -independent pathways, although an important fraction of the effects are PKC-mediated as in other SLC6 transporters [10, 13, 15, 36] . The involvement of MAPK signalling pathways triggered by Ras exchange factors can be discarded since we did not detect any reduction of PMA inhibition when blocking this upstream step. Instead, we found a minor, although reproducible, increase in GLYT2 inhibition by PMA in the presence of MAPK inhibitors, suggesting that these cascades may exert a protective effect on GLYT2 as reported for related transporters [44] [45] [46] [47] . Conversely, the results of the present study indicate that GLYT2 is most likely regulated by signalling pathways triggered by the small GTPase Rac1, which is involved in the regulation of the actin cytoskeleton [33] . It has been shown that Rac1 can be stimulated by PMA either directly or through the upstream action of PKC, and its activity can be regulated by chimaerins, non-PKC phorbol-ester receptors involved in actin cytoskeleton organization, cell adhesion, cellcycle progression, neurite outgrowth and neural development [31] [32] [33] [34] 48] . Recently, a SERT association with the actin cytoskeleton through the binding of the LIM adaptor protein Hic-5 preceding PMA-induced transporter internalization has been reported [19] . (A and B) , the indicated concentrations of PMA (C) or 500 nM PMA (D). The cells were extensively washed and surface biotinylated at 4 • C in steady-state conditions as described in Figure 1 (A) or glycine transport by GLYT2 was measured (B-D). The 100 % transport activity in (C) was 2.01 + − 0.2 nmol of glycine/mg of protein per 15 min. (E) Purified synaptosomes were pre-incubated with vehicle (DMSO) or 1 μM PMA for 30 min at 37 • C, solubilized in 0.5 % Triton X-100, fractionated through a sucrose gradient, and fractionated proteins were subjected to SDS/PAGE and immunoblotting. Gradient fractions 1-12 (from top to bottom) were probed for GLYT2 and the raft marker protein flotillin-1. (F) Average GLYT2 and flotillin-1 immunoreactivities in the Western blots of three independent gradients were analysed by densitometry. For every protein (GLYT2 and flotillin-1), immunoreactivity in the raft (4-6) and non-raft (9-12) fractions was expressed as a percentage of the total protein immunoreactivity in the whole gradient.
The involvement of the actin cytoskeleton in the regulation of GLYT2 also became apparent from our previous results [20] , and deserves further research. In addition, future studies addressing the physiological stimuli that trigger these regulatory pathways will be undertaken to understand the role of GLYT2 in glycinergic neurotransmission
